April 2024 • PharmaTimes Magazine • 36-37
// YOUR MOVES //
Your Moves
Mover of the Month
Aspire Pharma has announced the appointment of David Lawrence as Head of the new Out-Licensing Team.
David has joined Aspire during a period of significant growth for the company and will lead on Aspire’s efforts to forge business-to-business partnerships with the company’s niche product range and with a particular focus on certain markets in Europe and around the world.
He will play an important role in delivering Aspire’s growth strategy and mission to improve healthcare globally.
David brings over 30 years’ experience in the pharma industry including 22 years at Teva where he excelled originally in sales, then launch and project management. For the last seven years David has focused on business development, out-licensing across Europe and other markets around the world.
Meanwhile, Marina Passarell recently joined Aspire as Business Development Manager, Out-Licensing.
Marina has a scientific background, with an MBA in pharma, as well as strong industrial knowledge, bringing over ten years of international business development and out-licensing experience.
Nuclera has announced the appointment of Joseph Bertelsen as Chief Commercial Officer. With over 20 years’ commercial leadership experience in the life sciences tools and drug development industries, Joseph brings an extensive sales record that will be instrumental to the commercial launch of the company’s eProtein Discovery platform. Joseph joins Nuclera from the Institute for Protein Innovation, a research institute focused on providing synthetic antibodies, where he was the Director of Commercialisation responsible for establishing a sustainable antibody distribution entity.
Prior roles include SVP of Global Sales and Marketing at Diagenode, a life sciences company providing tools for molecular epigenetics research and infectious disease diagnostics, and Director of Sales at Abcam, a company specialising in the production and distribution of research antibodies.
Joseph enthused: “Nuclera is disrupting the protein market with their technology allowing researchers to more easily and quickly have access to proteins for their research. Their benchtop technology has the potential to greatly reduce costs and timelines associated with the drug discovery process.”
Ipsen has announced the appointment of Ioana Parsons as General Manager of the company’s UK & Ireland affiliate.
She joins from Ipsen Poland, where she has been General Manager for the past three years. As well as becoming UK & I General Manager, Ioana will act as Head of Site for Ipsen’s UK Global Hub.
Ioana Parsons said: “The UK has a complex healthcare landscape and I’m ready to tackle both the opportunities and the challenges we face here, working together with our dedicated healthcare partners in the U.K. and Ireland to ensure the best possible health outcomes for patients.
“Our passion continues to be about making a real impact on patients’ lives every day and we do this by discovering innovative medicines that truly make a difference,” she added.
Ioana has a wealth of experience working in the life Sciences industry including local, regional and global roles at major pharmaceutical companies.
In addition to this, she has worked as a consultant at McKinsey & Company in London, where she led large-scale strategy and commercial transformation projects for a range of global pharmaceutical clients.
Cuttsy+Cuttsy has announced the appointment of Jon Hume as Commercial Director.
Over the last two decades, Jon has gained extensive experience in agency commercial roles, client services and strategy.
He has worked closely with senior client stakeholders, building successful relationships, developing key accounts, creating new products and scaling agency teams. Alongside his comprehensive healthcare experience, Jon also enriches C+C with his expertise in digital and FMCG sectors.
In 2020, Jon was honoured in the BIMA 100 list as one of the leaders, pioneers, entrepreneurs and change-makers leading the digital sector, recognising his achievements in building and leading agency client services and project management teams.
Jon said: “After closely collaborating with C+C and their fantastic clients throughout most of 2023, I am privileged to take the next step and join this talented team. Their work significantly impacts patient lives every day and I am eager to contribute."
Nicox has appointed Gavin Spencer as Chief Executive Officer.
The appointment has immediate effect, following the Board’s decision to end the mandate of Andreas Segerros.
Gavin was most recently Executive Vice-President, Chief Business Officer & Head of Corporate Development at Nicox. He has spent more than 25 years in the life sciences industry and combines strong business acumen with a solid scientific background and broad strategic, financial, corporate development, commercial and operational management experience in biotechs and large pharma. During his time with Nicox, since 2005, Gavin Spencer has had a key role in building and managing Nicox’s partnerships, including closing agreements with Pfizer, Bausch + Lomb, VISUfarma and Ocumension Therapeutics.
He has also been involved in equity raising and investor relations at Nicox for many years and has led the Company’s recent financing activities.
Amylyx has announced the appointment of Andrew Caldwell as General Manager UK and Ireland. He joins the company with more than 30 years of life sciences industry experience including a decade spent in the commercialisation of rare and specialised disease therapies in the UK and Ireland.
Andrew has previously established and grown UK and Ireland-focused business entities for neurodegenerative disease specialist Orphazyme, and Akcea Therapeutics. He was also a former commercial lead for Alexion Pharmaceuticals and a core member of Merck Serono’s UK senior leadership team.
“Working as part of the Amylyx EMEA team, I’m determined to help advance our position in motor neurone disease, which has had no new treatment option in Europe for more than 25 years. Alongside this, I’m excited to be part of Amylyx’ progress in addressing other neurodegenerative diseases,” said Andrew.
Paul Adams has been announced as the new Chief Executive Officer of LloydsPharmacy Clinical Homecare, having joined at the end of last year.
This strategic move is poised to reshape the company’s position within the market to positively impact the landscape of clinical homecare delivery in the UK.
As a highly experienced CEO, with a robust background in driving change and growth within the healthcare sector, Paul is at the forefront of LloydsPharmacy Clinical Homecare’s mission to become a pioneer in bringing specialist clinical treatment therapies to patients.
"It’s a privilege to step into a role that has such a profound impact on the way healthcare is delivered," Paul said. "Our aim is to ensure that every patient has access to the vital healthcare they need, right in their own communities or homes, not only easing the load on the NHS but improving healthcare outcomes."
Besins Healthcare has announced the appointment of Irina Spirieva as its new General Manager for the UK and Ireland.
Irina joins the company after a period of significant growth and commitment to invest considerable resources to upscale the manufacturing and supply of its medicines to meet the exponential growth in demand in the UK. Irina joins BHUK with a wealth of experience in women’s health and global pharma including senior roles at Johnson & Johnson, Merck and Organon.
Irina said: “I am delighted to join Besins at a particularly exciting period in the company’s evolution as a leading provider of hormone replacement therapy medicines for women and also providing hormone treatments for men to both the NHS in the UK and to the Health Service Executive in Ireland."
Clinithink has appointed Mark Johnston as Chief Executive Officer. He succeeds Dr Chris Tackaberry who co-founded the company and will continue to lead its work in life sciences and population health.
Mark joins the company following successful leadership positions at Amazon Web Services and Microsoft where he focused on global expansion of their healthcare and life sciences businesses.
Mark is a proven executive who will focus on expanding the company’s growth through targeted go-to-market programmes and commercial development in the artificial intelligence market.
“I am delighted to welcome Mark Johnston to Clinithink as my successor in the role of Chief Executive Officer. Mark is a dynamic and talented executive with a great track record of success in scaled healthcare and life science technology organisations,” said Chris.
Mark added: “I am thrilled to work alongside the talented team at Clinithink and look forward to engaging with our employees, customers and partners.
“The proven capabilities that Clinithink has demonstrated are critical to unlock the value of unstructured data across use cases in healthcare delivery and payment, as well as life sciences research and commercial optimisation.”